Population Health Research Institute

CompanyROR

Population Health Research Institute develops one asset, in phase 3 (AMO-02 in arrhythmogenic cardiomyopathy). Mostly small molecule acting on GSK3B.

Assets
1
Furthest
Phase 3
Trials
30
Signals
2

Pipeline

1

  • AMO-02

    Inhibition of glycogen synthase kinase 3 beta (GSK3B).

    Phase 3Small moleculeGSK3Barrhythmogenic cardiomyopathyPartner

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms1
  • Trials39
  • Signals3
  • Similar companies2

Updated 7 Oct 2026 · 43 sources

Intelligence